Sector Alpha Week of 2026-08-04
20-quarter listed-company comparison

Biotechnology Stocks

Biotechnology: Vertex Pharmaceuticals Incorporated owns the largest revenue base; Ascendis Pharma A/S has the fastest current growth.

01 · the industry itself · before any single company

How has Biotechnology moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 114% ahead of S&P 500. Earnings across its companies fell 7% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 7 weeks running.

FADING · −14 in 4w~Price up, without the fundamentals confirming123 of 295 companies ahead of S&P 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more

RS ↑7w · 190/291 >200d (−23) · 123/295 lead (−14) · EPS 154/287↑

20050020262025202420232022 642348 TRAILING 12-MONTH EPS · 100 AT THE START0100Mar 22Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Mar 2022 · trailing 12-month earnings per share at 100, against 100 at the start · down 100.0% on a year ago · 31 reportingJun 2022 · trailing 12-month earnings per share at 99, against 100 at the start · down 100.0% on a year ago · 32 reportingSep 2022 · trailing 12-month earnings per share at 97, against 100 at the start · down 100.0% on a year ago · 32 reportingDec 2022 · trailing 12-month earnings per share at 49, against 100 at the start · down 100.0% on a year ago · 33 reportingMar 2023 · trailing 12-month earnings per share at 34, against 100 at the start · down 81.4% on a year ago · 33 reportingJun 2023 · trailing 12-month earnings per share at 8, against 100 at the start · down 100.0% on a year ago · 33 reportingSep 2023 · trailing 12-month earnings per share at 0, against 100 at the start · down 99.8% on a year ago · 33 reportingDec 2023 · trailing 12-month earnings per share at 0, against 100 at the start · down 89.7% on a year ago · 32 reportingMar 2024 · trailing 12-month earnings per share at 0, against 100 at the start · down 31.7% on a year ago · 32 reportingJun 2024 · trailing 12-month earnings per share at 0, against 100 at the start · down 100.0% on a year ago · 32 reportingSep 2024 · trailing 12-month earnings per share at 0, against 100 at the start · down 26.2% on a year ago · 32 reportingDec 2024 · trailing 12-month earnings per share at 0, against 100 at the start · up 10.2% on a year ago · 33 reportingMar 2025 · trailing 12-month earnings per share at 0, against 100 at the start · up 9.3% on a year ago · 32 reportingJun 2025 · trailing 12-month earnings per share at 0, against 100 at the start · down 19.2% on a year ago · 33 reportingSep 2025 · trailing 12-month earnings per share at 0, against 100 at the start · up 23.1% on a year ago · 32 reportingDec 2025 · trailing 12-month earnings per share at 0, against 100 at the start · down 6.8% on a year ago · 31 reportingMar 2026 · trailing 12-month earnings per share at 9, against 100 at the start · down 25.9% on a year ago · 30 reportingNot reported yet — earnings trail price by a quarter or two9 · Mar 26No earnings on file this far back — the price series reaches further than the filings do
20050020262025202420232022 642348 TRAILING 12-MONTH EPS · 100 AT THE START0100Mar 22Mar 23Mar 24Mar 25Mar 26Mar 2022 · trailing 12-month earnings per share at 100, against 100 at the start · down 100.0% on a year ago · 31 reportingJun 2022 · trailing 12-month earnings per share at 99, against 100 at the start · down 100.0% on a year ago · 32 reportingSep 2022 · trailing 12-month earnings per share at 97, against 100 at the start · down 100.0% on a year ago · 32 reportingDec 2022 · trailing 12-month earnings per share at 49, against 100 at the start · down 100.0% on a year ago · 33 reportingMar 2023 · trailing 12-month earnings per share at 34, against 100 at the start · down 81.4% on a year ago · 33 reportingJun 2023 · trailing 12-month earnings per share at 8, against 100 at the start · down 100.0% on a year ago · 33 reportingSep 2023 · trailing 12-month earnings per share at 0, against 100 at the start · down 99.8% on a year ago · 33 reportingDec 2023 · trailing 12-month earnings per share at 0, against 100 at the start · down 89.7% on a year ago · 32 reportingMar 2024 · trailing 12-month earnings per share at 0, against 100 at the start · down 31.7% on a year ago · 32 reportingJun 2024 · trailing 12-month earnings per share at 0, against 100 at the start · down 100.0% on a year ago · 32 reportingSep 2024 · trailing 12-month earnings per share at 0, against 100 at the start · down 26.2% on a year ago · 32 reportingDec 2024 · trailing 12-month earnings per share at 0, against 100 at the start · up 10.2% on a year ago · 33 reportingMar 2025 · trailing 12-month earnings per share at 0, against 100 at the start · up 9.3% on a year ago · 32 reportingJun 2025 · trailing 12-month earnings per share at 0, against 100 at the start · down 19.2% on a year ago · 33 reportingSep 2025 · trailing 12-month earnings per share at 0, against 100 at the start · up 23.1% on a year ago · 32 reportingDec 2025 · trailing 12-month earnings per share at 0, against 100 at the start · down 6.8% on a year ago · 31 reportingMar 2026 · trailing 12-month earnings per share at 9, against 100 at the start · down 25.9% on a year ago · 30 reportingNot reported yet — earnings trail price by a quarter or two9No earnings on file this far back — the price series reaches further than the filings do
Biotechnology, equal-weighted, based at 200 S&P 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 295 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

02 · sector relative strength, before individual stocks

Is Biotechnology outperforming S&P 500?

Biotechnology has outperformed S&P 500 by 45.8% over the last 52 weeks. Over 13 weeks the gap is a lead of 10.3%. 18 of 29 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Revolution Medicines, Inc. is the strongest against the sector itself at +56.1%.

+10.3%Sector vs S&P 500 · 13 weeks
+45.8%Sector vs S&P 500 · 52 weeks
18/29Stocks leading S&P 500
10/29Stocks leading sector

Sector metric: — as of latest available · unclassified · direction unavailable.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Biotechnology has outperformed S&P 500 by 45.8% over 52 weeks and 10.3% over 13 weeks. 18 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 10 of 29 beat the sector itself. Vertex Pharmaceuticals Incorporated leads with revenue of $12,218 million, based on 18 of 30 comparable companies through Mar 2026.

Companies
30
complete canonical membership
Combined market value
$728.6B
Vertex Pharmaceuticals Incorporated
Revenue growing
15/17
positive TTM year-on-year growth
Beating S&P 500
18/29
positive Mansfield relative strength
Comparing 5 of 30
03 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Exelixis, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 55.5% evidence confidence.
Royalty Pharma plc looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Corcept Therapeutics Incorporated has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Exelixis, Inc.EXEL 64.3/100Thin evidence · provisional56% evidence LEADER 20.7/35 Revenue — · PAT — · OPM change 7.5 pp 39% evidence 17.2/25 ROCE 10.8% · OPM 41.1% 76% evidence 11.3/20 P/E 14× · PEG — 15% evidence 15.1/20 RS sector 0.7% · RS bench 12.5% · 1Y 48.5%11 of 12 weeks ahead 100% evidence
Exact sum: 20.7 + 17.2 + 11.3 + 15.1 = 64.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
2Jazz Pharmaceuticals plcJAZZ 63.0/100Mixed-positive evidence74% evidence LEADER 21.5/35 Revenue 9.2% · PAT -93.8% · OPM change 37.7 pp 62% evidence 12.3/25 ROCE 3.4% · OPM 31.5% 76% evidence 14.2/20 P/E 16.6× · PEG 0.33 65% evidence 15.0/20 RS sector 17.7% · RS bench 30.2% · 1Y 135.1%12 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 12.3 + 14.2 + 15 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Krystal Biotech, Inc.KRYS 60.7/100Mixed-positive evidence81% evidence FADING 22.9/35 Revenue 25.2% · PAT 80.7% · OPM change 5 pp 83% evidence 13.2/25 ROCE 4.7% · OPM 46.1% 76% evidence 12.5/20 P/E 34.5× · PEG 0.8 65% evidence 12.1/20 RS sector 4.9% · RS bench 15.6% · 1Y 134.2%10 of 12 weeks ahead 100% evidence
Exact sum: 22.9 + 13.2 + 12.5 + 12.1 = 60.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Halozyme Therapeutics, Inc.HALO 58.9/100Mixed-positive evidence81% evidence BREAKING OUT 15.9/35 Revenue 39.2% · PAT -28.3% · OPM change -4.4 pp 83% evidence 16.8/25 ROCE 8.5% · OPM 49% 76% evidence 15.0/20 P/E 23.2× · PEG 0.27 65% evidence 11.2/20 RS sector -5.9% · RS bench 6.1% · 1Y 32.3%6 of 12 weeks ahead 100% evidence
Exact sum: 15.9 + 16.8 + 15 + 11.2 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Incyte CorporationINCY 58.9/100Thin evidence · provisional58% evidence BREAKING OUT 17.4/35 Revenue — · PAT — · OPM change 4.2 pp 45% evidence 17.7/25 ROCE 12.6% · OPM 23.7% 76% evidence 11.2/20 P/E 14.4× · PEG — 15% evidence 12.6/20 RS sector -2.1% · RS bench 9.5% · 1Y 53.8%8 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 17.7 + 11.2 + 12.6 = 58.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Roivant Sciences Ltd.ROIV 57.7/100Thin evidence · provisional60% evidence BREAKING OUT 20.2/35 Revenue -69% · PAT — · OPM change 20242.2 pp 62% evidence 12.2/25 ROCE 7.8% · OPM — 61% evidence 11.5/20 P/E 2× · PEG — 15% evidence 13.8/20 RS sector 16.6% · RS bench 28.1% · 1Y 201%7 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 12.2 + 11.5 + 13.8 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Corcept Therapeutics IncorporatedCORT 57.6/100Thin evidence · provisional58% evidence LEADER 17.0/35 Revenue — · PAT — · OPM change -32.3 pp 45% evidence 12.7/25 ROCE 5.9% · OPM -30.1% 76% evidence 8.5/20 P/E 207× · PEG — 15% evidence 19.4/20 RS sector 33.3% · RS bench 50.7% · 1Y 51.9%12 of 12 weeks ahead 100% evidence
Exact sum: 17 + 12.7 + 8.5 + 19.4 = 57.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Vertex Pharmaceuticals IncorporatedVRTX 55.5/100Mixed-positive evidence74% evidence BREAKING OUT 21.1/35 Revenue 10.1% · PAT — · OPM change 15.4 pp 62% evidence 15.1/25 ROCE 5.5% · OPM 38.1% 76% evidence 10.9/20 P/E 26.5× · PEG 1.2 65% evidence 8.4/20 RS sector -13.5% · RS bench -3.1% · 1Y 30.6%5 of 12 weeks ahead 100% evidence
Exact sum: 21.1 + 15.1 + 10.9 + 8.4 = 55.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Royalty Pharma plcRPRX 55.4/100Mixed-positive evidence81% evidence LEADER 12.1/35 Revenue 7.8% · PAT -23.1% · OPM change -4.7 pp 83% evidence 13.5/25 ROCE 3.2% · OPM 89.3% 76% evidence 14.3/20 P/E 25.1× · PEG 0.29 65% evidence 15.5/20 RS sector 3.7% · RS bench 15.4% · 1Y 53%11 of 12 weeks ahead 100% evidence
Exact sum: 12.1 + 13.5 + 14.3 + 15.5 = 55.4 · Decision use: Price leads the evidence: RS versus the benchmark is 15.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
10Regeneron Pharmaceuticals, Inc.REGN 49.2/100Thin evidence · provisional58% evidence TURNING 16.8/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence 13.5/25 ROCE 3.7% · OPM 17.8% 76% evidence 11.0/20 P/E 15.4× · PEG — 15% evidence 7.9/20 RS sector -11.6% · RS bench -1.1% · 1Y 35.1%1 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 13.5 + 11 + 7.9 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Genmab A/SGMAB 49.1/100Mixed-negative evidence81% evidence TURNING 14.9/35 Revenue 27.5% · PAT -19.9% · OPM change -6.2 pp 83% evidence 12.8/25 ROCE 2.1% · OPM 20.1% 76% evidence 15.7/20 P/E 20.4× · PEG 0.24 65% evidence 5.7/20 RS sector -19.9% · RS bench -9.8% · 1Y 35.4%2 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 12.8 + 15.7 + 5.7 = 49.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
12argenx SEARGX 48.8/100Thin evidence · provisional58% evidence TURNING 20.1/35 Revenue — · PAT — · OPM change 12.8 pp 45% evidence 13.6/25 ROCE 6.8% · OPM 30% 76% evidence 9.8/20 P/E 35.6× · PEG — 15% evidence 5.3/20 RS sector -16.7% · RS bench -6.6% · 1Y 27.6%7 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 13.6 + 9.8 + 5.3 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13BeOne Medicines AGONC 48.2/100Mixed-negative evidence64% evidence BASING 22.9/35 Revenue 37.4% · PAT — · OPM change 15.5 pp 62% evidence 11.1/25 ROCE 4.7% · OPM 16.5% 76% evidence 9.0/20 P/E 69.2× · PEG — 15% evidence 5.2/20 RS sector -18.8% · RS bench -8.2% · 1Y 12.1%0 of 12 weeks ahead 100% evidence
Exact sum: 22.9 + 11.1 + 9 + 5.2 = 48.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.8% and the one-year return is 12.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
14Bio-Techne CorporationTECH 47.4/100Mixed-negative evidence81% evidence BREAKING OUT 17.9/35 Revenue 0.3% · PAT -18.1% · OPM change 12 pp 83% evidence 12.9/25 ROCE 3.1% · OPM 24.2% 76% evidence 3.8/20 P/E 75.7× · PEG 7.7 65% evidence 12.8/20 RS sector -2.5% · RS bench 9.4% · 1Y 43%7 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 12.9 + 3.8 + 12.8 = 47.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Moderna, Inc.MRNA 46.7/100Thin evidence · provisional58% evidence FADING 18.1/35 Revenue — · PAT — · OPM change 615.4 pp 45% evidence 6.4/25 ROCE -8.6% · OPM -356.8% 76% evidence 9.3/20 P/E 44.8× · PEG — 15% evidence 12.9/20 RS sector 12.5% · RS bench 23.4% · 1Y 118.2%6 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 6.4 + 9.3 + 12.9 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16BridgeBio Pharma, Inc.BBIO 44.5/100Mixed-negative evidence61% evidence BREAKING OUT 18.2/35 Revenue 100% · PAT — · OPM change 35 pp 62% evidence 4.8/25 ROCE -16.5% · OPM -54.5% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 11.5/20 RS sector -2.5% · RS bench 8.5% · 1Y 76.2%3 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 4.8 + 10 + 11.5 = 44.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Alnylam Pharmaceuticals, Inc.ALNY 44.1/100Thin evidence · provisional58% evidence ASLEEP 21.6/35 Revenue — · PAT — · OPM change 20 pp 45% evidence 12.7/25 ROCE 6.3% · OPM 23% 76% evidence 9.1/20 P/E 56× · PEG — 15% evidence 0.7/20 RS sector -53% · RS bench -46.1% · 1Y -50.1%0 of 12 weeks ahead 100% evidence
Exact sum: 21.6 + 12.7 + 9.1 + 0.7 = 44.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Cytokinetics, IncorporatedCYTK 43.9/100Mixed-negative evidence61% evidence FADING 21.2/35 Revenue 100% · PAT — · OPM change 8907.6 pp 62% evidence 4.1/25 ROCE -16.9% · OPM -948.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 8.6/20 RS sector -1.3% · RS bench 9.6% · 1Y 130.5%10 of 12 weeks ahead 100% evidence
Exact sum: 21.2 + 4.1 + 10 + 8.6 = 43.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Insmed IncorporatedINSM 42.2/100Mixed-negative evidence61% evidence BASING 24.6/35 Revenue 100% · PAT — · OPM change 217.2 pp 62% evidence 5.4/25 ROCE -9.4% · OPM -50.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 2.2/20 RS sector -46.4% · RS bench -39.3% · 1Y -9.9%0 of 12 weeks ahead 100% evidence
Exact sum: 24.6 + 5.4 + 10 + 2.2 = 42.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -46.4% and the one-year return is -9.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
20Axsome Therapeutics, Inc.AXSM 40.0/100Mixed-negative evidence61% evidence FADING 16.4/35 Revenue 63.9% · PAT — · OPM change 13.8 pp 62% evidence 4.5/25 ROCE -20.2% · OPM -33.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.1/20 RS sector -0.4% · RS bench 10.2% · 1Y 102.5%10 of 12 weeks ahead 100% evidence
Exact sum: 16.4 + 4.5 + 10 + 9.1 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Arrowhead Pharmaceuticals, Inc.ARWR 40.0/100Thin evidence · provisional58% evidence LEADER 10.6/35 Revenue — · PAT — · OPM change -261.8 pp 45% evidence 6.6/25 ROCE -8.5% · OPM -191.6% 76% evidence 9.4/20 P/E 43.4× · PEG — 15% evidence 13.4/20 RS sector 25.5% · RS bench 37.3% · 1Y 445.6%11 of 12 weeks ahead 100% evidence
Exact sum: 10.6 + 6.6 + 9.4 + 13.4 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22ABIVAX Société AnonymeABVX 39.9/100Thin evidence · provisional57% evidence ASLEEP 19.8/35 Revenue -66.7% · PAT — · OPM change 564.8 pp 62% evidence 5.5/25 ROCE -20.6% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 4.6/20 RS sector -9.2% · RS bench 1% · 1Y 78.5%3 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 5.5 + 10 + 4.6 = 39.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Revolution Medicines, Inc.RVMD 39.4/100Thin evidence · provisional53% evidence LEADER 9.1/35 Revenue — · PAT — · OPM change -23854 pp 52% evidence 5.2/25 ROCE -21.3% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 15.1/20 RS sector 56.1% · RS bench 69.1% · 1Y 452.7%12 of 12 weeks ahead 100% evidence
Exact sum: 9.1 + 5.2 + 10 + 15.1 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Madrigal Pharmaceuticals, Inc.MDGL 35.9/100Thin evidence · provisional55% evidence ASLEEP 16.2/35 Revenue — · PAT — · OPM change 28 pp 45% evidence 6.8/25 ROCE -6.7% · OPM -29.8% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 2.9/20 RS sector -17.3% · RS bench -7.4% · 1Y 46.8%1 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 6.8 + 10 + 2.9 = 35.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25BioNTech SEBNTX 35.3/100Mixed-negative evidence64% evidence BASING 13.9/35 Revenue 1% · PAT — · OPM change -237.7 pp 62% evidence 7.6/25 ROCE -3.5% · OPM -456.2% 76% evidence 8.7/20 P/E 194.3× · PEG — 15% evidence 5.1/20 RS sector -27% · RS bench -17.4% · 1Y -18.2%0 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 7.6 + 8.7 + 5.1 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26BioMarin Pharmaceutical Inc.BMRN 32.5/100Adverse evidence81% evidence TURNING 8.7/35 Revenue 9.9% · PAT -48.7% · OPM change -13.1 pp 83% evidence 10.5/25 ROCE 1.8% · OPM 16.9% 76% evidence 5.2/20 P/E 41.2× · PEG 5.86 65% evidence 8.1/20 RS sector -14.4% · RS bench -3.6% · 1Y 5.9%3 of 12 weeks ahead 100% evidence
Exact sum: 8.7 + 10.5 + 5.2 + 8.1 = 32.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27Ascendis Pharma A/SASND 55.4/100Thin evidence · provisional44% evidence ASLEEP 25.2/35 Revenue 100% · PAT — · OPM change 113.3 pp 62% evidence 10.1/25 ROCE 4.7% · OPM 10.1% 76% evidence 10.1/20 P/E 26.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —2 of 3 weeks ahead 0% evidence
Exact sum: 25.2 + 10.1 + 10.1 + 10 = 55.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Apogee Therapeutics, Inc.APGE 52.3/100Thin evidence · provisional47% evidence LEADER 15.4/35 Revenue — · PAT — · OPM change — 33% evidence 7.4/25 ROCE -8.5% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 19.5/20 RS sector 46.5% · RS bench 59.8% · 1Y 279.2%12 of 12 weeks ahead 100% evidence
Exact sum: 15.4 + 7.4 + 10 + 19.5 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Nuvalent, Inc.NUVL 46.2/100Thin evidence · provisional47% evidence 16.3/35 Revenue — · PAT — · OPM change — 33% evidence 6.5/25 ROCE -10.5% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 13.4/20 RS sector -1.8% · RS bench 15.9% · 1Y 48.6%5 of 9 weeks ahead 100% evidence
Exact sum: 16.3 + 6.5 + 10 + 13.4 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Summit Therapeutics Inc.SMMT 41.6/100Thin evidence · provisional47% evidence BASING 12.5/35 Revenue — · PAT — · OPM change — 33% evidence 17.2/25 ROCE 48.3% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 1.9/20 RS sector -40% · RS bench -31.3% · 1Y -52%0 of 12 weeks ahead 100% evidence
Exact sum: 12.5 + 17.2 + 10 + 1.9 = 41.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
Showing 10 of 30 companies
04 · what price has already done

Market action

Revolution Medicines, Inc. has the strongest one-year price move in Biotechnology at +452.7%. It also leads on Mansfield relative strength against the S&P 500 at +69.1%. 18 of 29 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.

Price and relative strength

Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

05 · compare level, then change

Revenue Scale & Growth Durability

Vertex Pharmaceuticals Incorporated has the highest Revenue among the 30 Biotechnology companies compared here, at $12,218 million. BeOne Medicines AG is next at $5,738 million. Ascendis Pharma A/S has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies. Its Revenue series carries 19 reported observations across the 20-quarter window.

What the numbers say: Vertex Pharmaceuticals Incorporated is the scale leader at $12,218 million, 112.9% ahead of BeOne Medicines AG. Ascendis Pharma A/S's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 135% from a $867 million base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderVertex Pharmaceuticals Incorporated · $12,218 million
Gap112.9% versus #2 · BeOne Medicines AG
Persistence8/8 recent comparable periods
Coverage18/30 companies · 472 observations

Investor read: Vertex Pharmaceuticals Incorporated is the scale benchmark; Ascendis Pharma A/S is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Vertex Pharmaceuticals Incorporated's growth falls below Ascendis Pharma A/S's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Vertex Pharmaceuticals Incorporated VRTX$12.2B
2BeOne Medicines AG ONC$5.7B
3Jazz Pharmaceuticals plc JAZZ$4.4B
4Genmab A/S GMAB$3.9B
5BioMarin Pharmaceutical Inc. BMRN$3.2B
Revenue growthfastest growers
1Ascendis Pharma A/S ASND100%
2BridgeBio Pharma, Inc. BBIO100%
3Cytokinetics, Incorporated CYTK100%
4Insmed Incorporated INSM100%
5Axsome Therapeutics, Inc. AXSM64%
Revenue · company comparison
18/30 level · 17/30 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
Regeneron Pharmaceuticals, Inc. REGN$3.6B19%Jun 2026
Vertex Pharmaceuticals Incorporated VRTX$3.0B7.8%Mar 2026
BeOne Medicines AG ONC$1.5B35%Mar 2026
argenx SE ARGX$1.3B63%Jun 2026
Incyte Corporation INCY$1.3B21%Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY$1.2B96%Jun 2026
Jazz Pharmaceuticals plc JAZZ$1.1B19%Mar 2026
Genmab A/S GMAB$896M25%Mar 2026
BioMarin Pharmaceutical Inc. BMRN$766M2.8%Mar 2026
Royalty Pharma plc RPRX$631M11%Mar 2026
Exelixis, Inc. EXEL$611M10%Jun 2026
Moderna, Inc. MRNA$389M260%Jun 2026
Halozyme Therapeutics, Inc. HALO$377M42%Mar 2026
Madrigal Pharmaceuticals, Inc. MDGL$311M127%Jun 2026
Bio-Techne Corporation TECH$311M-1.6%Mar 2026
Insmed Incorporated INSM$306M229%Mar 2026
Ascendis Pharma A/S ASND$247M145%Mar 2026
BridgeBio Pharma, Inc. BBIO$195M67%Mar 2026
Axsome Therapeutics, Inc. AXSM$191M58%Mar 2026
Corcept Therapeutics Incorporated CORT$165M5.1%Jun 2026
BioNTech SE BNTX$149M-39%Mar 2026
Krystal Biotech, Inc. KRYS$116M32%Mar 2026
Arrowhead Pharmaceuticals, Inc. ARWR$74M-86%Mar 2026
Cytokinetics, Incorporated CYTK$19M850%Mar 2026
Roivant Sciences Ltd. ROIV$3M-63%Mar 2026
Revolution Medicines, Inc. RVMD$1M-93%Mar 2026
ABIVAX Société Anonyme ABVX$1M0.0%Mar 2026
Full 20-quarter history · every available company

Revenue · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

$188M
$259M
$213M
$225M
$264M
$335M
$319M
$319M
$751M
$440M
$494M
$660M
$501M
$593M
$594M
$774M
$1.2B
$1.1B
$1.2B
—

argenx SE · ARGX

$7M
$34M
$31M
$85M
$146M
$182M
$230M
$281M
$340M
$418M
$413M
$489M
$589M
$761M
$807M
$967M
$1.2B
$1.3B
$1.3B
—

BeOne Medicines AG · ONC

$206M
$214M
$307M
$342M
$388M
$380M
$448M
$595M
$781M
$631M
$752M
$929M
$1.0B
$1.1B
$1.1B
$1.3B
$1.4B
$1.5B
$1.5B
—

BioNTech SE · BNTX

$6.1B
$5.5B
$6.4B
$3.2B
$3.5B
$4.3B
$1.3B
$168M
$895M
$1.5B
$188M
$129M
$1.2B
$1.2B
$244M
$261M
$1.5B
$907M
$149M
—

Incyte Corporation · INCY

$813M
$863M
$733M
$911M
$823M
$927M
$809M
$955M
$919M
$1.0B
$881M
$1.0B
$1.1B
$1.2B
$1.1B
$1.2B
$1.4B
$1.5B
$1.3B
—

Insmed Incorporated · INSM

$47M
$56M
$53M
$65M
$68M
$59M
$65M
$77M
$79M
$84M
$76M
$90M
$93M
$104M
$93M
$107M
$142M
$264M
$306M
—

Moderna, Inc. · MRNA

$5.0B
$7.2B
$6.1B
$4.7B
$3.4B
$5.1B
$1.9B
$344M
$1.8B
$2.8B
$167M
$241M
$1.9B
$966M
$108M
$142M
$1.0B
$678M
$389M
—

Regeneron Pharmaceuticals, Inc. · REGN

$3.5B
$5.0B
$3.0B
$2.9B
$2.9B
$3.4B
$3.2B
$3.2B
$3.4B
$3.4B
$3.1B
$3.5B
$3.7B
$3.8B
$3.0B
$3.7B
$3.8B
$3.9B
$3.6B
—

Revolution Medicines, Inc. · RVMD

$1M
$9M
$8M
$9M
$3M
$15M
$7M
$4M
—
$1M
—
—
—
—
—
—
—
—
—
—

Roivant Sciences Ltd. · ROIV

$14M
$24M
$9M
$4M
$13M
$17M
$27M
$22M
$4M
$16M
$9M
$8M
$4M
$9M
$8M
$2M
$2M
$2M
$3M
—

Royalty Pharma plc · RPRX

$586M
$576M
$562M
$536M
$573M
$566M
$684M
$538M
$536M
$596M
$568M
$537M
$565M
$594M
$568M
$579M
$609M
$622M
$631M
—

Vertex Pharmaceuticals Incorporated · VRTX

$2.0B
$2.1B
$2.1B
$2.2B
$2.3B
$2.3B
$2.4B
$2.5B
$2.5B
$2.5B
$2.7B
$2.6B
$2.8B
$2.9B
$2.8B
$3.0B
$3.1B
$3.2B
$3.0B
—

Revenue growth · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

—
—
—
1.8%
40%
29%
50%
42%
184%
31%
55%
107%
-33%
35%
20%
17%
149%
85%
96%
—

argenx SE · ARGX

—
—
—
-73%
1,986%
435%
642%
231%
133%
130%
80%
74%
73%
82%
95%
98%
95%
74%
63%
—

BeOne Medicines AG · ONC

—
—
—
128%
88%
78%
46%
74%
101%
66%
68%
56%
28%
79%
49%
42%
41%
33%
35%
—

BioNTech SE · BNTX

—
1,504%
—
—
-43%
-23%
-80%
-95%
-74%
-65%
-85%
-23%
39%
-20%
30%
102%
22%
-24%
-39%
—

Incyte Corporation · INCY

—
—
—
29%
1.2%
7.4%
10%
4.8%
12%
9.3%
8.9%
9.3%
24%
16%
20%
16%
20%
28%
21%
—

Insmed Incorporated · INSM

—
—
—
44%
45%
5.4%
23%
18%
16%
42%
17%
17%
18%
24%
22%
19%
53%
154%
229%
—

Moderna, Inc. · MRNA

—
—
—
9.1%
-32%
-30%
-69%
-93%
-46%
-45%
-91%
-30%
1.7%
-66%
-35%
-41%
-45%
-30%
260%
—

Regeneron Pharmaceuticals, Inc. · REGN

—
—
—
-44%
-15%
-31%
6.6%
11%
15%
0.6%
-0.5%
12%
11%
10%
-3.7%
3.6%
0.9%
2.5%
19%
—

Revolution Medicines, Inc. · RVMD

—
—
—
0.0%
200%
67%
-13%
-56%
—
-93%
—
—
—
—
—
—
—
—
—
—

Roivant Sciences Ltd. · ROIV

—
—
—
-50%
-7.1%
-29%
200%
450%
-69%
-5.9%
-67%
-64%
0.0%
-44%
-11%
-75%
-50%
-78%
-63%
—

Royalty Pharma plc · RPRX

—
—
—
-3.4%
-2.2%
-1.7%
22%
0.4%
-6.5%
5.3%
-17%
-0.2%
5.4%
-0.3%
0.0%
7.8%
7.8%
4.7%
11%
—

Vertex Pharmaceuticals Incorporated · VRTX

—
—
—
22%
18%
11%
13%
14%
6.4%
9.3%
13%
6.1%
12%
16%
2.9%
12%
11%
9.6%
7.8%
—
06 · compare level, then change

Operating Economics & Margin Trend

Royalty Pharma plc has the highest OPM among the 30 Biotechnology companies compared here, at 89.3%. Halozyme Therapeutics, Inc. is next at 49%. Roivant Sciences Ltd. has the highest Margin change at +20242.2 percentage points, so level and change sit with different companies. 24 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Royalty Pharma plc leads opm at 89.3%; Roivant Sciences Ltd. leads margin change at +20242.2 percentage points.

LeaderRoyalty Pharma plc · 89.3%
Gap82.2% versus #2 · Halozyme Therapeutics, Inc.
Persistence4/8 recent comparable periods
Coverage24/30 companies · 403 observations

Investor read: Royalty Pharma plc sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Royalty Pharma plc RPRX89%
2Halozyme Therapeutics, Inc. HALO49%
3Krystal Biotech, Inc. KRYS46%
4Exelixis, Inc. EXEL41%
5Vertex Pharmaceuticals Incorporated VRTX38%
Margin changefastest expanders
1Roivant Sciences Ltd. ROIV+20,242.2 pp
2Cytokinetics, Incorporated CYTK+8,907.6 pp
3Moderna, Inc. MRNA+615.4 pp
4ABIVAX Société Anonyme ABVX+564.8 pp
5Insmed Incorporated INSM+217.2 pp
Operating margin · company comparison
24/30 level · 27/30 change
All-company data · latest reported quarter
CompanyOPMMargin changeReported
Royalty Pharma plc RPRX89%−4.7 ppMar 2026
Halozyme Therapeutics, Inc. HALO49%−4.4 ppMar 2026
Krystal Biotech, Inc. KRYS46%+5.0 ppMar 2026
Exelixis, Inc. EXEL41%+7.5 ppJun 2026
Vertex Pharmaceuticals Incorporated VRTX38%+15.4 ppMar 2026
Jazz Pharmaceuticals plc JAZZ32%+37.7 ppMar 2026
argenx SE ARGX30%+12.8 ppJun 2026
Bio-Techne Corporation TECH24%+12.0 ppMar 2026
Incyte Corporation INCY24%+4.2 ppJun 2026
Alnylam Pharmaceuticals, Inc. ALNY23%+20.0 ppJun 2026
Genmab A/S GMAB20%−6.2 ppMar 2026
Regeneron Pharmaceuticals, Inc. REGN18%−1.7 ppJun 2026
BioMarin Pharmaceutical Inc. BMRN17%−13.1 ppMar 2026
BeOne Medicines AG ONC17%+15.5 ppMar 2026
Ascendis Pharma A/S ASND10%+113.3 ppMar 2026
Madrigal Pharmaceuticals, Inc. MDGL-30%+28.0 ppJun 2026
Corcept Therapeutics Incorporated CORT-30%−32.3 ppJun 2026
Axsome Therapeutics, Inc. AXSM-33%+13.8 ppMar 2026
Insmed Incorporated INSM-50%+217.2 ppMar 2026
BridgeBio Pharma, Inc. BBIO-55%+35.0 ppMar 2026
Arrowhead Pharmaceuticals, Inc. ARWR-192%−261.8 ppMar 2026
Moderna, Inc. MRNA-357%+615.4 ppJun 2026
Revolution Medicines, Inc. RVMD-403%−23,854.0 ppMar 2026
BioNTech SE BNTX-456%−237.7 ppMar 2026
Roivant Sciences Ltd. ROIV-855%+20,242.2 ppMar 2026
Cytokinetics, Incorporated CYTK-949%+8,907.6 ppMar 2026
ABIVAX Société Anonyme ABVX-993%+564.8 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

-97%
-75%
-69%
-85%
-98%
-56%
-47%
-72%
29%
-27%
-8.8%
7.4%
-15%
-18%
3.0%
-2.1%
30%
12%
23%
—

argenx SE · ARGX

—
-686%
-708%
-205%
-142%
-63%
-45%
-36%
-24%
-33%
-23%
-9.3%
2.4%
14%
17%
21%
30%
28%
30%
—

BeOne Medicines AG · ONC

-224%
-267%
-145%
-129%
-113%
-123%
-83%
-54%
-17%
-61%
-35%
-12%
-12%
-7.0%
1.0%
6.7%
12%
12%
17%
—

BioNTech SE · BNTX

78%
85%
75%
69%
69%
77%
51%
-336%
8.2%
36%
-270%
-751%
0.8%
13%
-219%
-192%
-3.1%
-36%
-456%
—

Incyte Corporation · INCY

29%
13%
16%
28%
17%
7.6%
3.1%
20%
23%
19%
10%
-46%
13%
26%
20%
44%
33%
22%
24%
—

Insmed Incorporated · INSM

-222%
-177%
-169%
-135%
-189%
-255%
-227%
-305%
-187%
-213%
-193%
-320%
-228%
-221%
-267%
-291%
-257%
-121%
-50%
—

Moderna, Inc. · MRNA

72%
75%
70%
52%
35%
31%
-20%
-543%
-110%
0.2%
-758%
-566%
-3.8%
-129%
-972%
-639%
-26%
-126%
-357%
—

Regeneron Pharmaceuticals, Inc. · REGN

54%
53%
42%
39%
42%
34%
30%
32%
33%
28%
24%
30%
32%
26%
20%
29%
27%
23%
18%
—

Revolution Medicines, Inc. · RVMD

—
-559%
-765%
-681%
—
-403%
—
—
—
—
—
—
—
—
—
—
—
—
—
—

Roivant Sciences Ltd. · ROIV

—
—
—
—
—
—
-855%
—
—
—
—
—
—
—
—
—
—
—
—
—

Royalty Pharma plc · RPRX

52%
27%
39%
71%
34%
-85%
70%
46%
28%
103%
-13%
50%
130%
61%
94%
36%
70%
62%
89%
—

Vertex Pharmaceuticals Incorporated · VRTX

53%
42%
50%
50%
48%
45%
33%
41%
42%
39%
42%
-133%
40%
35%
23%
39%
39%
38%
38%
—

Margin change · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

—
—
—
−19.0 pp
−0.8 pp
+19.0 pp
+21.9 pp
+13.2 pp
+126.1 pp
+29.8 pp
+38.1 pp
+79.5 pp
−43.9 pp
+8.8 pp
+11.8 pp
−9.5 pp
+44.9 pp
+29.7 pp
+20.0 pp
—

argenx SE · ARGX

—
—
—
−234.6 pp
+2,854.9 pp
+622.7 pp
+662.4 pp
+168.6 pp
+118.7 pp
+29.6 pp
+22.5 pp
+27.0 pp
+26.1 pp
+46.7 pp
+39.8 pp
+30.1 pp
+27.7 pp
+14.3 pp
+12.8 pp
—

BeOne Medicines AG · ONC

—
—
—
+188.0 pp
+110.9 pp
+143.9 pp
+61.7 pp
+75.1 pp
+96.0 pp
+62.4 pp
+48.1 pp
+42.0 pp
+5.1 pp
+53.9 pp
+35.8 pp
+18.2 pp
+23.5 pp
+19.4 pp
+15.5 pp
—

BioNTech SE · BNTX

—
+14.2 pp
—
—
−8.6 pp
−7.9 pp
−23.4 pp
−405.0 pp
−60.8 pp
−41.4 pp
−321.6 pp
−414.8 pp
−7.4 pp
−23.1 pp
+51.9 pp
+558.6 pp
−3.9 pp
−48.1 pp
−237.7 pp
—

Incyte Corporation · INCY

—
—
—
+7.9 pp
−12.2 pp
−5.2 pp
−12.8 pp
−7.6 pp
+6.6 pp
+10.9 pp
+7.3 pp
−66.1 pp
−10.6 pp
+7.1 pp
+9.1 pp
+89.4 pp
+19.7 pp
−3.3 pp
+4.2 pp
—

Insmed Incorporated · INSM

—
—
—
+59.8 pp
+33.1 pp
−78.9 pp
−58.0 pp
−169.6 pp
+1.7 pp
+42.4 pp
+34.5 pp
−14.8 pp
−41.6 pp
−7.6 pp
−74.6 pp
+28.5 pp
−28.7 pp
+99.4 pp
+217.2 pp
—

Moderna, Inc. · MRNA

—
—
—
−18.8 pp
−36.9 pp
−43.9 pp
−89.4 pp
−594.2 pp
−144.6 pp
−30.9 pp
−738.4 pp
−22.9 pp
+106.1 pp
−129.2 pp
−214.1 pp
−73.1 pp
−21.8 pp
+2.6 pp
+615.4 pp
—

Regeneron Pharmaceuticals, Inc. · REGN

—
—
—
−26.3 pp
−11.8 pp
−19.7 pp
−12.5 pp
−6.6 pp
−8.7 pp
−5.3 pp
−6.0 pp
−2.0 pp
−1.3 pp
−2.2 pp
−4.4 pp
−0.8 pp
−4.3 pp
−3.4 pp
−1.7 pp
—

Revolution Medicines, Inc. · RVMD

—
—
—
−169.1 pp
+2,548.1 pp
+156.8 pp
−306.8 pp
−2,164.0 pp
—
−23,854.0 pp
—
—
—
—
—
—
—
—
—
—

Roivant Sciences Ltd. · ROIV

—
—
—
−4,540.5 pp
+2,653.1 pp
−1,206.5 pp
+2,037.4 pp
+5,258.1 pp
−3,623.0 pp
+35,165.8 pp
−1,437.7 pp
−1.2 pp
−1,772.8 pp
−35,991.2 pp
−1,471.3 pp
−11,850.5 pp
−11,856.9 pp
−13,923.5 pp
+20,242.2 pp
—

Royalty Pharma plc · RPRX

—
—
—
−63.7 pp
−18.2 pp
−111.9 pp
+30.9 pp
−24.3 pp
−5.3 pp
+188.1 pp
−83.0 pp
+4.0 pp
+102.0 pp
−41.9 pp
+107.0 pp
−13.9 pp
−60.1 pp
+1.5 pp
−4.7 pp
—

Vertex Pharmaceuticals Incorporated · VRTX

—
—
—
+52.5 pp
−4.8 pp
+2.6 pp
−16.8 pp
−9.2 pp
−6.5 pp
−5.6 pp
+9.6 pp
−174.1 pp
−1.5 pp
−4.1 pp
−19.7 pp
+171.7 pp
−1.7 pp
+2.6 pp
+15.4 pp
—
07 · compare level, then change

Profit Scale & Acceleration

Vertex Pharmaceuticals Incorporated has the highest Net profit among the 30 Biotechnology companies compared here, at $4,338 million. Royalty Pharma plc is next at $1,359 million. Krystal Biotech, Inc. has the highest Profit growth at 80.7%, so level and change sit with different companies. 21 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Vertex Pharmaceuticals Incorporated leads with $4,338 million of TTM profit, 219.2% above Royalty Pharma plc. Krystal Biotech, Inc. shows 80.7% growth from a $224 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderVertex Pharmaceuticals Incorporated · $4,338 million
Gap219.2% versus #2 · Royalty Pharma plc
Persistence5/8 recent comparable periods
Coverage21/30 companies · 565 observations

Investor read: Vertex Pharmaceuticals Incorporated sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Vertex Pharmaceuticals Incorporated VRTX$4.3B
2Royalty Pharma plc RPRX$1.4B
3Genmab A/S GMAB$866M
4BeOne Medicines AG ONC$513M
5Ascendis Pharma A/S ASND$495M
Profit growthfastest growers
1Krystal Biotech, Inc. KRYS81%
2Bio-Techne Corporation TECH-18%
3Genmab A/S GMAB-20%
4Royalty Pharma plc RPRX-23%
5Halozyme Therapeutics, Inc. HALO-28%
Net profit · company comparison
21/30 level · 6/30 change
All-company data · latest reported quarter
CompanyNet profitProfit growthReported
Vertex Pharmaceuticals Incorporated VRTX$1.0B60%Mar 2026
Regeneron Pharmaceuticals, Inc. REGN$727M-10%Jun 2026
Ascendis Pharma A/S ASND$629M—Mar 2026
Royalty Pharma plc RPRX$468M7.8%Mar 2026
argenx SE ARGX$366M117%Jun 2026
Roivant Sciences Ltd. ROIV$356M-104%Mar 2026
Incyte Corporation INCY$303M92%Jun 2026
Jazz Pharmaceuticals plc JAZZ$293M6.8%Mar 2026
BeOne Medicines AG ONC$227M-156%Mar 2026
Exelixis, Inc. EXEL$210M31%Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY$206M-176%Jun 2026
Halozyme Therapeutics, Inc. HALO$150M27%Mar 2026
BioMarin Pharmaceutical Inc. BMRN$106M-43%Mar 2026
Genmab A/S GMAB$74M-70%Mar 2026
Krystal Biotech, Inc. KRYS$56M56%Mar 2026
Bio-Techne Corporation TECH$51M122%Mar 2026
Summit Therapeutics Inc. SMMT$12M50%Jun 2026
Corcept Therapeutics Incorporated CORT$-32M-252%Jun 2026
ABIVAX Société Anonyme ABVX$-48M—Mar 2026
Axsome Therapeutics, Inc. AXSM$-65M—Mar 2026
Apogee Therapeutics, Inc. APGE$-74M—Mar 2026
Madrigal Pharmaceuticals, Inc. MDGL$-94M—Jun 2026
Nuvalent, Inc. NUVL$-109M—Mar 2026
Arrowhead Pharmaceuticals, Inc. ARWR$-138M-138%Mar 2026
Insmed Incorporated INSM$-164M—Mar 2026
BridgeBio Pharma, Inc. BBIO$-167M—Mar 2026
Cytokinetics, Incorporated CYTK$-206M—Mar 2026
Revolution Medicines, Inc. RVMD$-454M—Mar 2026
BioNTech SE BNTX$-532M-217%Mar 2026
Moderna, Inc. MRNA$-1.3B-1,638%Jun 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

$-205M
$-258M
$-240M
$-277M
$-406M
$-207M
$-174M
$-276M
$148M
$-138M
$-66M
$-17M
$-112M
$-84M
$-18M
$-66M
$251M
$186M
$206M
—

argenx SE · ARGX

$-234M
$-238M
$-227M
$-209M
$-235M
$-39M
$-29M
$-94M
$-73M
$-99M
$-62M
$29M
$91M
$774M
$169M
$245M
$344M
$533M
$366M
—

BeOne Medicines AG · ONC

$-438M
$-586M
$-434M
$-566M
$-558M
$-445M
$-348M
$-381M
$215M
$-5.7B
$-251M
$-120M
$-121M
$-152M
$1M
$94M
$125M
$67M
$227M
—

BioNTech SE · BNTX

$3.2B
$3.2B
$3.7B
$1.7B
$1.8B
$2.3B
$502M
$-190M
$161M
$458M
$-315M
$-808M
$198M
$260M
$-416M
$-387M
$-29M
$-305M
$-532M
—

Incyte Corporation · INCY

$182M
$564M
$38M
$161M
$113M
$28M
$22M
$204M
$171M
$201M
$170M
$-445M
$106M
$201M
$158M
$405M
$424M
$299M
$303M
—

Insmed Incorporated · INSM

$-113M
$-113M
$-95M
$-96M
$-131M
$-160M
$-160M
$-245M
$-159M
$-186M
$-157M
$-301M
$-221M
$-236M
$-257M
$-322M
$-370M
$-328M
$-164M
—

Moderna, Inc. · MRNA

$3.3B
$4.9B
$3.7B
$2.2B
$1.0B
$1.5B
$79M
$-1.4B
$-3.6B
$217M
$-1.2B
$-1.3B
$13M
$-1.1B
$-971M
$-825M
$-200M
$-826M
$-1.3B
—

Regeneron Pharmaceuticals, Inc. · REGN

$1.6B
$2.2B
$974M
$852M
$1.3B
$1.2B
$818M
$968M
$1.0B
$1.2B
$722M
$1.4B
$1.3B
$918M
$809M
$1.4B
$1.5B
$845M
$727M
—

Revolution Medicines, Inc. · RVMD

$-53M
$-53M
$-58M
$-61M
$-73M
$-57M
$-68M
$-98M
$-108M
$-162M
$-116M
$-133M
$-156M
$-195M
$-213M
$-248M
$-305M
$-365M
$-454M
—

Roivant Sciences Ltd. · ROIV

$-226M
$-306M
$-291M
$-354M
$-316M
$-385M
$-175M
$-328M
$-245M
$5.1B
$-95M
$-32M
$-237M
$-209M
$-252M
$-274M
$-166M
$-314M
$356M
—

Royalty Pharma plc · RPRX

$222M
$54M
$128M
$492M
$220M
$-610M
$509M
$351M
$122M
$718M
$-4M
$194M
$806M
$334M
$434M
$91M
$444M
$356M
$468M
—

Vertex Pharmaceuticals Incorporated · VRTX

$852M
$770M
$762M
$811M
$931M
$819M
$700M
$916M
$1.0B
$969M
$1.1B
$-3.6B
$1.0B
$913M
$646M
$1.0B
$1.1B
$1.2B
$1.0B
—

Profit growth · reported quarter history

Showing the 12 largest of 20 companies with a series here. The remaining 8 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

—
—
—
—
—
—
—
—
—
—
—
—
-176%
—
—
—
—
—
—
—

argenx SE · ARGX

—
—
—
-301%
—
—
—
—
—
—
—
—
—
—
—
745%
278%
-31%
117%
—

BeOne Medicines AG · ONC

—
—
—
—
—
—
—
—
—
—
—
—
-156%
—
—
—
—
—
—
—

BioNTech SE · BNTX

—
763%
—
—
-44%
-28%
-86%
-111%
-91%
-80%
-163%
—
23%
-43%
—
—
-115%
-217%
—
—

Genmab A/S · GMAB

—
—
—
443%
145%
41%
-55%
-26%
-12%
20%
519%
3.6%
-38%
178%
27%
66%
116%
-88%
-70%
—

Incyte Corporation · INCY

—
—
—
8.1%
-38%
-95%
-42%
27%
51%
618%
673%
-318%
-38%
0.0%
-7.1%
—
300%
49%
92%
—

Jazz Pharmaceuticals plc · JAZZ

—
—
—
—
—
—
1,067%
186%
—
—
-119%
59%
46%
101%
—
-525%
17%
6.8%
—
—

Moderna, Inc. · MRNA

—
—
—
-21%
-69%
-70%
-98%
-163%
-448%
-85%
-1,587%
—
—
-616%
—
—
-1,638%
—
—
—

Regeneron Pharmaceuticals, Inc. · REGN

—
—
—
-73%
-19%
-46%
-16%
14%
-23%
-3.1%
-12%
48%
33%
-21%
12%
-2.8%
8.9%
-8.0%
-10%
—

Roivant Sciences Ltd. · ROIV

—
—
—
—
—
—
—
—
—
—
—
—
—
-104%
—
—
—
—
—
—

Royalty Pharma plc · RPRX

—
—
—
-39%
-0.9%
-1,230%
298%
-29%
-45%
—
-101%
-45%
561%
-53%
—
-53%
-45%
6.6%
7.8%
—

Vertex Pharmaceuticals Incorporated · VRTX

—
—
—
1,110%
9.3%
6.4%
-8.1%
13%
11%
18%
57%
-492%
1.0%
-5.8%
-41%
—
3.6%
30%
60%
—
08 · compare level, then change

Return On Capital Employed

Summit Therapeutics Inc. has the highest ROCE among the 30 Biotechnology companies compared here, at 48.3%. Incyte Corporation is next at 12.6%. Ascendis Pharma A/S has the highest ROCE change at +120.8 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Summit Therapeutics Inc. leads ROCE at 48.3%, 35.7 percentage points above Incyte Corporation. Ascendis Pharma A/S has the strongest latest improvement at +120.8 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderSummit Therapeutics Inc. · 48.3%
Gap283.3% versus #2 · Incyte Corporation
Persistence6/8 recent comparable periods
Coverage30/30 companies · 569 observations

Investor read: Summit Therapeutics Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Summit Therapeutics Inc. SMMT48%
2Incyte Corporation INCY13%
3Exelixis, Inc. EXEL11%
4Halozyme Therapeutics, Inc. HALO8.5%
5Roivant Sciences Ltd. ROIV7.8%
ROCE changefastest improvers
1Ascendis Pharma A/S ASND+120.8 pp
2ABIVAX Société Anonyme ABVX+14.9 pp
3Roivant Sciences Ltd. ROIV+12.5 pp
4Insmed Incorporated INSM+12.2 pp
5Alnylam Pharmaceuticals, Inc. ALNY+6.8 pp
Return on capital · company comparison
30/30 level · 30/30 change
All-company data · latest reported quarter
CompanyROCEROCE changeReported
Summit Therapeutics Inc. SMMT48%−196.0 ppJun 2026
Incyte Corporation INCY13%−0.9 ppJun 2026
Exelixis, Inc. EXEL11%+3.1 ppJun 2026
Halozyme Therapeutics, Inc. HALO8.5%+1.0 ppMar 2026
Roivant Sciences Ltd. ROIV7.8%+12.5 ppMar 2026
argenx SE ARGX6.8%+2.9 ppJun 2026
Alnylam Pharmaceuticals, Inc. ALNY6.3%+6.8 ppJun 2026
Corcept Therapeutics Incorporated CORT5.9%+1.7 ppJun 2026
Vertex Pharmaceuticals Incorporated VRTX5.5%+2.3 ppMar 2026
BeOne Medicines AG ONC4.7%+4.4 ppMar 2026
Ascendis Pharma A/S ASND4.7%+120.8 ppMar 2026
Krystal Biotech, Inc. KRYS4.7%+0.7 ppMar 2026
Regeneron Pharmaceuticals, Inc. REGN3.7%+0.5 ppJun 2026
Jazz Pharmaceuticals plc JAZZ3.4%+4.0 ppMar 2026
Royalty Pharma plc RPRX3.2%−0.1 ppMar 2026
Bio-Techne Corporation TECH3.1%+1.6 ppMar 2026
Genmab A/S GMAB2.1%−1.4 ppMar 2026
BioMarin Pharmaceutical Inc. BMRN1.8%−1.8 ppMar 2026
BioNTech SE BNTX-3.5%+1.9 ppMar 2026
Madrigal Pharmaceuticals, Inc. MDGL-6.7%−1.4 ppJun 2026
Arrowhead Pharmaceuticals, Inc. ARWR-8.5%−42.5 ppMar 2026
Apogee Therapeutics, Inc. APGE-8.5%0.0 ppMar 2026
Moderna, Inc. MRNA-8.6%−1.0 ppJun 2026
Insmed Incorporated INSM-9.4%+12.2 ppMar 2026
Nuvalent, Inc. NUVL-11%+0.6 ppMar 2026
BridgeBio Pharma, Inc. BBIO-17%−2.0 ppMar 2026
Cytokinetics, Incorporated CYTK-17%+0.2 ppMar 2026
Axsome Therapeutics, Inc. AXSM-20%−5.1 ppMar 2026
ABIVAX Société Anonyme ABVX-21%+14.9 ppMar 2026
Revolution Medicines, Inc. RVMD-21%−9.3 ppMar 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

-6.4%
-6.7%
-5.3%
-6.8%
-9.2%
-6.6%
-5.4%
-8.7%
7.6%
-4.1%
-1.6%
1.7%
-2.6%
-3.6%
0.6%
-0.5%
12%
4.0%
7.8%
6.3%

argenx SE · ARGX

-9.5%
-10%
-7.5%
-5.9%
-7.8%
-4.3%
-3.5%
-3.5%
-2.3%
-4.0%
-2.6%
-1.3%
0.3%
2.1%
2.7%
3.9%
5.4%
5.7%
5.4%
6.8%

BeOne Medicines AG · ONC

-10%
-10%
-7.8%
-8.6%
-9.4%
-7.9%
-6.5%
-6.2%
-2.8%
-8.6%
-6.2%
-2.6%
-3.0%
-2.1%
0.3%
2.2%
3.6%
3.7%
4.7%
—

BioNTech SE · BNTX

86%
67%
—
—
16%
20%
6.4%
-5.5%
0.4%
2.6%
-4.9%
-9.5%
0.1%
0.7%
-5.4%
-5.1%
-0.2%
-1.6%
-3.5%
—

Incyte Corporation · INCY

7.6%
3.2%
3.2%
6.7%
3.5%
1.6%
0.6%
4.1%
4.4%
3.7%
1.7%
-11%
3.3%
6.5%
4.2%
14%
10%
7.3%
6.1%
13%

Insmed Incorporated · INSM

-11%
-11%
-11%
-8.5%
-12%
-12%
-13%
-22%
-15%
-14%
-14%
-23%
-15%
-16%
-22%
-18%
-20%
-18%
-9.4%
—

Moderna, Inc. · MRNA

50%
59%
37%
18%
7.7%
8.7%
-1.9%
-9.8%
-12%
0.0%
-7.2%
-8.5%
-0.5%
-9.1%
-8.3%
-7.6%
-2.2%
-7.7%
-14%
-8.6%

Regeneron Pharmaceuticals, Inc. · REGN

11%
15%
6.6%
5.3%
5.5%
4.8%
3.8%
3.9%
4.2%
3.5%
2.6%
3.6%
3.8%
3.1%
1.8%
3.2%
3.0%
2.5%
1.8%
3.7%

Revolution Medicines, Inc. · RVMD

-8.6%
-8.8%
-8.3%
-9.6%
-11%
-8.6%
-9.1%
-14%
-15%
-14%
-9.9%
-12%
-14%
-10%
-12%
-13%
-17%
-16%
-21%
—

Roivant Sciences Ltd. · ROIV

-49%
-9.8%
-11%
-13%
-12%
-16%
-10%
-13%
-11%
114%
-4.6%
-2.5%
-9.2%
-4.3%
-4.7%
-5.1%
-5.8%
-6.3%
7.8%
—

Royalty Pharma plc · RPRX

1.8%
0.9%
1.3%
2.2%
1.1%
-2.9%
2.9%
1.5%
0.9%
3.8%
-0.5%
1.6%
4.5%
2.2%
3.3%
1.2%
2.4%
2.2%
3.2%
—

Vertex Pharmaceuticals Incorporated · VRTX

11%
8.3%
9.4%
9.5%
9.1%
7.7%
5.6%
6.8%
6.4%
5.7%
6.3%
-21%
6.1%
5.4%
3.2%
6.3%
6.1%
5.9%
5.5%
—

ROCE change · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

—
—
—
—
−2.8 pp
+0.1 pp
−0.1 pp
−1.9 pp
+16.8 pp
+2.5 pp
+3.8 pp
+10.4 pp
−10.2 pp
+0.5 pp
+2.2 pp
−2.2 pp
+14.3 pp
+7.6 pp
+7.2 pp
+6.8 pp

argenx SE · ARGX

—
—
—
—
+1.7 pp
+6.0 pp
+4.0 pp
+2.4 pp
+5.5 pp
+0.3 pp
+0.9 pp
+2.2 pp
+2.6 pp
+6.1 pp
+5.3 pp
+5.2 pp
+5.1 pp
+3.6 pp
+2.7 pp
+2.9 pp

BeOne Medicines AG · ONC

—
—
—
—
+1.0 pp
+2.1 pp
+1.3 pp
+2.4 pp
+6.6 pp
−0.7 pp
+0.3 pp
+3.6 pp
−0.2 pp
+6.5 pp
+6.5 pp
+4.8 pp
+6.6 pp
+5.8 pp
+4.4 pp
—

BioNTech SE · BNTX

—
—
—
—
−69.5 pp
−46.6 pp
—
—
−15.7 pp
−17.6 pp
−11.3 pp
−4.0 pp
−0.3 pp
−1.9 pp
−0.5 pp
+4.4 pp
−0.3 pp
−2.3 pp
+1.9 pp
—

Incyte Corporation · INCY

—
—
—
—
−4.1 pp
−1.6 pp
−2.6 pp
−2.6 pp
+0.9 pp
+2.1 pp
+1.1 pp
−15.5 pp
−1.1 pp
+2.8 pp
+2.5 pp
+24.9 pp
+7.1 pp
+0.8 pp
+1.9 pp
−0.9 pp

Insmed Incorporated · INSM

—
—
—
—
−1.8 pp
−0.7 pp
−1.6 pp
−13.2 pp
−2.5 pp
−2.1 pp
−1.5 pp
−1.2 pp
+0.3 pp
−2.4 pp
−7.5 pp
+4.8 pp
−5.0 pp
−1.8 pp
+12.2 pp
—

Moderna, Inc. · MRNA

—
—
—
—
−42.6 pp
−49.8 pp
−39.3 pp
−28.2 pp
−19.4 pp
−8.7 pp
−5.3 pp
+1.3 pp
+11.2 pp
−9.1 pp
−1.1 pp
+0.9 pp
−1.7 pp
+1.4 pp
−5.4 pp
−1.0 pp

Regeneron Pharmaceuticals, Inc. · REGN

—
—
—
—
−5.5 pp
−9.9 pp
−2.8 pp
−1.4 pp
−1.3 pp
−1.3 pp
−1.2 pp
−0.3 pp
−0.4 pp
−0.4 pp
−0.8 pp
−0.4 pp
−0.8 pp
−0.6 pp
0.0 pp
+0.5 pp

Revolution Medicines, Inc. · RVMD

—
—
—
—
−2.1 pp
+0.2 pp
−0.8 pp
−4.3 pp
−4.2 pp
−4.9 pp
−0.8 pp
+2.3 pp
+1.1 pp
+3.5 pp
−2.1 pp
−1.8 pp
−3.4 pp
−6.2 pp
−9.3 pp
—

Roivant Sciences Ltd. · ROIV

—
—
—
—
+37.2 pp
−6.6 pp
+0.8 pp
−0.8 pp
+0.4 pp
+130.0 pp
+5.8 pp
+10.8 pp
+2.1 pp
−117.9 pp
−0.1 pp
−2.6 pp
+3.4 pp
−2.0 pp
+12.5 pp
—

Royalty Pharma plc · RPRX

—
—
—
—
−0.7 pp
−3.8 pp
+1.6 pp
−0.7 pp
−0.2 pp
+6.7 pp
−3.4 pp
+0.1 pp
+3.6 pp
−1.6 pp
+3.8 pp
−0.4 pp
−2.1 pp
0.0 pp
−0.1 pp
—

Vertex Pharmaceuticals Incorporated · VRTX

—
—
—
—
−1.4 pp
−0.6 pp
−3.8 pp
−2.7 pp
−2.7 pp
−2.0 pp
+0.7 pp
−27.7 pp
−0.3 pp
−0.3 pp
−3.1 pp
+27.2 pp
0.0 pp
+0.5 pp
+2.3 pp
—
09 · compare level, then change

Valuation Against Growth & Quality

Genmab A/S has the lowest PEG among the 30 Biotechnology companies compared here, at 0.24×. Halozyme Therapeutics, Inc. is next at 0.27×. Roivant Sciences Ltd. has the lowest P/E at 2.04×, so level and change sit with different companies. 8 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Genmab A/S has the lowest comparable PEG at 0.24×, 11.1% below Halozyme Therapeutics, Inc.. Only 8 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderGenmab A/S · 0.24×
Gap11.1% versus #2 · Halozyme Therapeutics, Inc.
Persistence0/8 recent comparable periods
Coverage8/30 companies · 35 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
1Genmab A/S GMAB0.2
2Halozyme Therapeutics, Inc. HALO0.3
3Royalty Pharma plc RPRX0.3
4Jazz Pharmaceuticals plc JAZZ0.3
5Krystal Biotech, Inc. KRYS0.8
P/Elowest P/E
1Roivant Sciences Ltd. ROIV2.0
2Exelixis, Inc. EXEL14.0
3Incyte Corporation INCY14.4
4Regeneron Pharmaceuticals, Inc. REGN15.4
5Jazz Pharmaceuticals plc JAZZ16.6
Valuation · company comparison
8/30 level · 20/30 change
All-company data · latest reported quarter
CompanyPEGP/EReported
Corcept Therapeutics Incorporated CORT10.4207.0Jun 2026
Bio-Techne Corporation TECH7.775.7Mar 2026
BioMarin Pharmaceutical Inc. BMRN5.941.2Mar 2026
Regeneron Pharmaceuticals, Inc. REGN2.215.4Jun 2026
Vertex Pharmaceuticals Incorporated VRTX1.226.5Mar 2026
Exelixis, Inc. EXEL1.014.0Jun 2026
argenx SE ARGX0.835.6Jun 2026
Krystal Biotech, Inc. KRYS0.834.5Mar 2026
Jazz Pharmaceuticals plc JAZZ0.316.6Mar 2026
Royalty Pharma plc RPRX0.325.1Mar 2026
Halozyme Therapeutics, Inc. HALO0.323.3Mar 2026
Genmab A/S GMAB0.220.4Mar 2026
BeOne Medicines AG ONC—69.2Mar 2026
Alnylam Pharmaceuticals, Inc. ALNY—56.0Jun 2026
Roivant Sciences Ltd. ROIV—2.0Mar 2026
Incyte Corporation INCY—14.4Jun 2026
BioNTech SE BNTX—194.3Mar 2026
Moderna, Inc. MRNA—44.8Jun 2026
Ascendis Pharma A/S ASND—26.8Mar 2026
Arrowhead Pharmaceuticals, Inc. ARWR—43.4Mar 2026
Full 20-quarter history · every available company

PEG · reported quarter history

argenx SE · ARGX

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.8
0.8
—

Bio-Techne Corporation · TECH

—
—
—
—
—
—
3.9
7.7
—
—
—
—
—
—
—
—
—
—
—
—

BioMarin Pharmaceutical Inc. · BMRN

—
—
—
—
—
—
—
—
—
5.9
—
—
—
—
—
—
—
—
—
—

Corcept Therapeutics Incorporated · CORT

—
—
—
—
—
—
—
—
—
4.4
0.8
0.8
0.7
1.3
10.4
—
—
—
—
—

Exelixis, Inc. · EXEL

—
—
—
—
—
—
—
—
—
3.0
1.0
—
—
—
—
—
—
—
—
—

Genmab A/S · GMAB

—
—
—
—
—
—
—
1.4
—
—
—
1.5
3.8
—
0.2
—
—
—
—
—

Halozyme Therapeutics, Inc. · HALO

—
—
—
—
—
—
—
—
0.8
0.4
—
0.4
—
—
0.3
—
0.3
—
—
—

Jazz Pharmaceuticals plc · JAZZ

—
—
—
—
—
—
—
—
—
—
—
—
—
0.3
—
—
—
—
—
—

Krystal Biotech, Inc. · KRYS

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.8
—
—
—
—

Regeneron Pharmaceuticals, Inc. · REGN

—
—
—
—
—
—
—
—
—
—
—
—
1.7
1.8
1.0
2.6
—
2.2
—
—

Royalty Pharma plc · RPRX

—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.3
0.3
—
—
—
—

Vertex Pharmaceuticals Incorporated · VRTX

—
—
—
—
—
—
0.8
—
5.1
3.6
1.2
—
—
—
—
—
—
—
—
—

P/E · reported quarter history

Showing the 12 largest of 20 companies with a series here. The remaining 8 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alnylam Pharmaceuticals, Inc. · ALNY

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
912.0
170.7
91.4
56.0

argenx SE · ARGX

—
—
—
—
—
—
—
—
—
—
—
—
—
48.1
36.5
28.3
31.7
43.0
32.5
35.6

BeOne Medicines AG · ONC

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
873.6
123.0
69.2
—

BioNTech SE · BNTX

—
5.7
—
3.2
3.5
3.7
4.6
5.7
9.2
24.9
194.3
—
—
—
—
—
—
—
—
—

Genmab A/S · GMAB

59.9
58.2
69.6
38.2
27.7
35.6
32.3
35.5
35.3
33.2
24.7
20.6
22.9
11.9
11.1
10.4
13.1
20.0
20.4
—

Incyte Corporation · INCY

28.5
17.2
18.9
17.9
17.0
52.8
49.8
38.2
30.6
23.7
17.3
168.4
472.1
460.5
189.2
15.5
14.2
15.4
13.3
14.4

Jazz Pharmaceuticals plc · JAZZ

—
—
—
—
—
—
—
—
147.1
20.2
24.8
18.3
15.7
14.2
16.6
—
—
—
—
—

Moderna, Inc. · MRNA

23.6
9.0
5.1
4.4
4.3
8.9
13.3
44.8
—
—
—
—
—
—
—
—
—
—
—
—

Regeneron Pharmaceuticals, Inc. · REGN

9.7
8.8
9.9
11.8
14.5
18.9
22.3
19.0
23.5
25.3
28.4
27.8
26.0
18.6
16.2
13.2
13.5
18.6
18.8
15.4

Roivant Sciences Ltd. · ROIV

—
—
—
—
—
—
—
—
—
2.2
2.0
1.9
2.0
—
—
—
—
—
—
—

Royalty Pharma plc · RPRX

18.6
26.8
27.1
39.7
35.3
395.2
48.7
56.9
71.4
11.1
17.2
17.6
11.1
13.4
12.7
15.7
20.1
21.7
25.1
—

Vertex Pharmaceuticals Incorporated · VRTX

21.8
24.4
27.5
22.8
22.8
22.5
25.1
27.2
26.1
29.3
27.1
—
—
—
—
31.8
27.6
29.6
26.5
—
10 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Biotechnology comparison names 4 specific ways its own evidence can mislead, all listed below. All 30 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still be a low-base artefact.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
11 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 30 Biotechnology companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-04. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-04 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
12 · questions investors ask, short speakable answers

Biotechnology company comparison FAQs

These 22 answers restate the Biotechnology comparison above in question form. Every one is computed from the same 30 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.

Is the Biotechnology sector outperforming S&P 500?

Biotechnology has outperformed S&P 500 by 45.8% over 52 weeks and 10.3% over 13 weeks. 18 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 10 of 29 beat the sector itself.

Which Biotechnology company is largest by revenue?

Vertex Pharmaceuticals Incorporated leads with revenue of $12,218 million, based on 18 of 30 comparable companies through Mar 2026.

Which Biotechnology company is growing fastest?

Ascendis Pharma A/S has the fastest current revenue growth at 100%, across 17 of 30 comparable companies.

Which Biotechnology company has the strongest 4-Factor Sector Score?

Exelixis, Inc. ranks first at 64.3/100 with 55.5% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Biotechnology company has the lowest comparable PEG?

Genmab A/S has the lowest comparable PEG at 0.24, among 8 of 30 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Biotechnology comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Which Biotechnology company is the biggest?

Vertex Pharmaceuticals Incorporated is the largest, with trailing-twelve-month revenue of $12,218 million, ahead of BeOne Medicines AG at $5,738 million. That covers 18 of 30 companies with comparable reporting through Mar 2026.

Which Biotechnology company has the best profit margins?

Royalty Pharma plc has the highest operating margin at 89.3%, from 24 of 30 comparable companies. Roivant Sciences Ltd. shows the biggest recent improvement, at +20242.2 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Biotechnology company makes the most profit?

Vertex Pharmaceuticals Incorporated earns the most, at $4,338 million of trailing-twelve-month net profit, from 21 of 30 comparable companies. Krystal Biotech, Inc. has the fastest profit growth at 80.7%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Biotechnology company earns the highest return on capital?

Summit Therapeutics Inc. leads on return on capital employed at 48.3%, across 30 of 30 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Biotechnology stock is the cheapest?

On PEG — where a LOWER number is cheaper — Genmab A/S screens cheapest at 0.24×. Only 8 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Biotechnology sector beating the market?

Biotechnology has outperformed S&P 500 by 45.8% over the last 52 weeks and 10.3% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 18 of 29 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Biotechnology stock has the strongest price momentum?

Revolution Medicines, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Biotechnology company scores highest for research priority?

Exelixis, Inc. scores 64.3 out of 100 with 55.5% evidence confidence, from 20.7 points on growth and earnings, 17.2 on capital efficiency, 11.3 on valuation and 15.1 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Biotechnology companies does this comparison cover, and over what period?

It compares 30 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Biotechnology sector?

The 30 Biotechnology companies on this page carry $728,599 million of combined market value. Vertex Pharmaceuticals Incorporated is the largest at $121,256 million, about 17% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.

What is the Biotechnology sector's P/E ratio?

The median price-to-earnings ratio across the 30 Biotechnology companies on this page is 34.5×, measured on the 20 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.

How is the Biotechnology sector performing?

18 of the 29 covered Biotechnology companies are beating S&P 500 on Mansfield relative strength. The sector itself is 45.8% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.

How many Biotechnology stocks are listed in the US?

This comparison covers 30 listed Biotechnology companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI